Fosun Pharma unit gets green light for cancer drug trial
Shanghai Fosun Pharmaceutical Group announced that its holding subsidiary, Jiangsu XingSheng New Drug Research, received approval from China's National Medical Products Administration (NMPA) to conduct clinical trials for XS-03, a Class 1 chemical drug. The trials will evaluate XS-03 in combination with FOLFOX or FOLFIRI and bevacizumab for treating RAS-mutated metastatic colorectal cancer. Fosun Pharma intends to conduct Phase Ib/II clinical trials for this treatment regimen in mainland China. XS-03, an independently developed small molecule PLK1 inhibitor, has shown promising preclinical efficacy and safety. As of January 2025, the company has invested approximately RMB 20 million in research and development for this treatment strategy.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Shanghai Fosun Pharmaceutical Group publishes news
Free account required • Unsubscribe anytime